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Abstract: One-third of patients with epilepsy continue to have seizures despite current 
treatments, indicating the need for better antiseizure medications with novel mechanisms of 
action. Ezogabine (retigabine) has recently been approved for adjunctive treatment of partial-
onset seizures in adult patients with epilepsy. Ezogabine utilizes a novel mechanism of action, 
involving activation of specific potassium channels. The most common side effects of ezogabine 
are shared by most antiseizure medications and primarily consist of central nervous system 
(CNS) symptoms, such as somnolence, dizziness, confusion, and fatigue. In addition, a small 
percentage of patients on ezogabine experience a unique adverse effect affecting the bladder, 
which results in urinary hesitancy; thus, patients on ezogabine should be monitored carefully for 
potential urological symptoms. Overall, ezogabine appears to be well tolerated and represents 
a reasonable new option for treating patients with intractable epilepsy.
Keywords: antiepileptic drug, seizure, bladder, potassium channels
Introduction
Epilepsy is a common disease with a cumulative lifetime risk of at least 3%.1 It is asso-
ciated with significant morbidity and mortality, as well as decreased quality of life in 
a variety of social, educational, and vocational measures.2–4 Specifically, mortality has 
been demonstrated to be up to threefold higher in developed countries.5 Further, adults 
with seizures are at risk for lower levels of education, higher rates of unemployment, 
and psychological and physical ailments.6 A number of new antiseizure medications 
have been developed and marketed in the last two decades. Despite these new therapies, 
medically intractable epilepsy, defined as persistent seizures after an adequate trial 
of two appropriate antiseizure medications, continues to occur in approximately one-
third of cases.7,8 This makes the development of antiseizure medications with novel 
mechanisms of action an important goal to further broaden the possible success in 
intractable epilepsy of various etiologies. However, with novel mechanisms of action 
there is a risk of unique side effects.
One of these new antiseizure medications with a novel mechanism of action is 
ezogabine (EZG). EZG is an ethyl N-(2-amino-4-{[(4-fluorophenyl)methyl]amino}
phenyl) (Figure 1) and is known by the international nonproprietary name of “retigabine” 
in Europe and most of the world. This drug was recently approved by the European 
Medicines Agency and the US Food and Drug Administration (FDA) for adjunctive 
treatment of partial-onset seizures in adults. It appears to work by a unique mechanism 
of action compared with other currently available antiepileptic drugs. A number of 
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other recent reviews have also highlighted different aspects 
of EZG,9–13 but this review focuses especially on the adverse 
effects of EZG.
Mechanism of action
First developed through the National Institutes of Health 
Antiepileptic Drug Development program after the identi-
fication of a structural analog’s (flupirtine) efficacy against 
seizures, EZG’s mechanism of action is novel among 
currently available antiseizure medications.14 EZG exerts 
its effects on the Kv7 family of potassium channels15,16 by 
binding to the cytoplasmic aspects of the S5 and S6 parts of 
the activation gate of these potassium channels involved in 
the M-current.17,18 In doing so, EZG increases rates of channel 
opening, maintains potassium channels in the open state for 
longer periods of time, and alters the voltage characteristics 
of the cell, making channel opening more likely.16
The channels bound by EZG consist of the Kv7 homo- 
and heteromeric subunits KCNQ2–5.15,16,19 EZG’s primary 
site of action is the KCNQ2/3 heteromer,15,16 which is 
expressed in the nervous system and accounts for its 
antiseizure efficacy. There is no enhancement of the potas-
sium currents mediated by the KCNQ1 channel subunit, 
which is found primarily in cardiac tissue18 and also in the 
gastrointestinal system and brain.20 However, KCNQ4 and 
KCNQ5 potassium channels are activated by EZG and may 
be found in cochlear hair cells21 or smooth muscle.22 EZG 
causes relaxation of smooth muscle in the bladder, which 
probably accounts for the adverse effects of EZG on urinary 
function.23
Metabolism–drug interactions
EZG is absorbed rapidly after oral administration, with a 
peak plasma concentration at 1.5 hours after ingestion.24 
EZG is metabolized primarily by acetylation and glucuroni-
dation in the liver and is subsequently eliminated by renal 
excretion.25,26 Due to this dual metabolism, it is recom-
mended that individuals with low creatinine clearance 
(,50 mL/min), undergoing hemodialysis, or with moderate 
to severe hepatic impairment start at a lower starting dose 
(50 mg/d) and titrate to a lower maximum dose (600 mg/d 
for renal failure or severe hepatic impairment; 750 mg/d for 
moderate hepatic impairment). In patients 66–81 years of 
age, it has been noted that EZG clearance was diminished 
compared with younger study participants (18–40 years of 
age) and the authors attributed this to the normal decrease 
in creatinine clearance that occurs with age. No side effects 
from this difference were noted.27
As in vitro studies have demonstrated little or no potential 
for EZG to inhibit or induce the major cytochrome,28 P450 
isoenzymes, minimal drug interactions of clinical signifi-
cance have been reported. EZG does not interact with oral 
contraceptive agents.29 Moreover, it seems to be well tolerated 
in individuals taking other antiseizure medications as well, 
with minimal direct interactions. While EZG and lamotrigine 
had reciprocal effects on renal clearance, both drugs were 
tolerated equally well alone and in combination, thus these 
interactions were not thought clinically significant.30 No clini-
cally significant interactions have been found between EZG 
and propofol, valproate, or imipramine26 and an in vivo study 
has demonstrated lack of interaction between phenobarbitone 
and EZG.31 In clinical studies, no significant pharmacokinetic 
effect has been seen on phenytoin, carbamazepine, valproic 
acid or topiramate.32 Overall, EZG has few clinically signifi-
cant interactions with other pharmaceutical agents.
Efficacy
Three double-blind placebo-controlled multicenter trials have 
taken place investigating the efficacy of EZB in adults with 
medically intractable partial-onset epilepsy as add-on therapy 
in combination with other antiepileptic medications.33–35 
A recent paper has reported an integrated analysis of these 
three controlled trials.36 After pooling data from the three 
studies, 1240 patients were included, with 813 patients 
randomized to EZG and 427 to placebo. In all trials, after 
an initial 8-week baseline phase, patients were randomized 
to placebo or EZB (titrated to 600, 900, or 1200 mg/day, 
depending on the trial), followed by an 8–12-week main-
tenance phase. Two primary efficacy measures were used: 
(1) responder rate, defined as the percentage of patients expe-
riencing a $50% reduction in seizure frequency compared 
with the baseline phase; and (2) the percent change in partial 
seizure frequency. A number of secondary efficacy endpoints 
were also assessed, including more specific categorization 
of seizure frequency reduction rates and the proportion of 
seizure-free days and seizure-free patients.
Analysis of the integrated data found statistically 








Figure 1 Chemical structure of ezogabine.
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measures.36 Responder rates ($50% reduction in seizure 
frequency) were 35% and 45% for EZG at 600 and 
900 mg/day, respectively, compared with 21% for placebo 
(P , 0.001) and 50% for EZG at 1200 mg/day, compared 
with 24% for placebo (P , 0.001). Average reduction in 
seizure frequency was 26%, 37%, and 39% for 600, 900, and 
1200 mg/d EZG, respectively, all of which were statistically 
significantly greater than placebo (15%). Similar differences 
were observed in various secondary endpoints. For example, 
the proportion of patients experiencing a 50%–75% or $75% 
reduction in seizures showed a dose-dependent increase 
with EZG compared with placebo. At all doses, there was a 
significant increase in seizure-free days with EZG compared 
with placebo, although the effect was modest (81%–84% for 
EZG vs 78% for placebo). In addition, while in the individual 
trials there had been no statistically significant effect of EZG 
on the percentage of seizure-free patients, in the pooled 
analysis of EZG at 1200 mg/d, but not at 600 or 900 mg/d, 
there was a statistically significant increase in the proportion 
of seizure-free patients during the maintenance phase (15% 
with 1200 mg/d EZG vs 5% with placebo).
Subgroup analyses did not demonstrate any differ-
ences in the magnitude of the effect of EZG based on age 
(18–44 years vs .44 years), sex, race (white vs nonwhite), 
region (US vs non-US), number of baseline antiseizure 
medications, and seizure subtypes (simple partial, complex 
partial, secondary generalized). Overall, these randomized 
placebo-controlled trials demonstrated that EZG is effective 
as add-on therapy for adults with intractable partial-onset 
epilepsy. The magnitude of the effects of EZG on seizures 
is similar to most other new antiseizure medications used as 
adjunctive therapy for intractable epilepsy and only a small 
percentage of patients become seizure-free on EZG.
Adverse events
Over the course of the three major placebo-controlled 
trials,33–35 EZG was generally quite well tolerated. Based 
on the pooled analysis, adverse events that were con-
sidered severe were similar in the placebo (10%), EZG 
600 mg/d (10%), and EZG 900 mg/d (12%) groups but 
were higher in the EZG 1200 mg/d group (20%).36 All other 
adverse events were noted by investigators to be mild to 
moderate. Three deaths (0.7%) related to sudden death in 
epilepsy, injury, and respiratory failure occurred in the 427 
patients on placebo, whereas only two deaths (0.2%) in the 
cumulative EZG groups due to sudden death in epilepsy and 
diabetic ketoacidosis occurred in the 813 patients. Discon-
tinuation of the study due to adverse events occurred in 10%, 
15%, 24%, and 28% of patients in the placebo, 600 mg/d, 
900 mg/d, and 1200 mg/d groups, respectively.36
Reasons for discontinuation of the study and the over-
all most common adverse events were generally central 
nervous system (CNS) related (Table 1). These adverse 
events occurred with increasing frequency as the dose of 
EZG was increased. The most common side effects included 
dizziness and somnolence and, to a lesser extent, confusion, 
fatigue, and asthenia.33–35 Porter et al33 noted speech difficul-
ties in no patients in the placebo arms and five (5%), twelve 
(12.6%), and 17 (16%) patients in the 600 mg/d, 900 mg/d, 
and 1200 mg/d arms, respectively.
EZG has been noted to decrease gastrointestinal smooth 
muscle contractility.37,38 Constipation was not mentioned 
Table 1 Adverse effects of ezogabine reported in at least 5% of patients with intractable partial seizures in placebo-controlled add-on 
clinical trials
Placebo,  
n = 427 (%)
Ezogabine 600 mg/d,  
n = 281 (%)
Ezogabine 900 mg/d,  
n = 273 (%)
Ezogabine 1200 mg/d, 
n = 259 (%)
Dizziness 38 (8.9) 41 (14.6) 64 (23.4) 84 (32.4)
Somnolence 51 (11.9) 43 (15.3) 67 (24.5) 69 (26.6)
Confusion 11 (2.6) 12 (4.3) 21 (7.7) 42 (16.2)
Headache 68 (15.9) 34 (12.1) 47 (17.2) 39 (15.1)
Fatigue 25 (5.9) 45 (16) 40 (14.7) 34 (13.1)
Coordination disturbance 12 (2.8) 14 (5) 14 (5.1) 30 (11.6)
Blurred vision 9 (2.1) 5 (1.8) 12 (4.4) 27 (10.4)
Memory impairment 11 (2.6) 7 (2.5) 15 (5.5) 24 (9.3)
Vertigo 9 (2.1) 22 (7.8) 21 (7.7) 24 (9.3)
Nausea 22 (5.2) 18 (6.4) 17 (6.2) 22 (8.5)
Attention disturbance 4 (,1) 17 (6) 15 (5.5) 17 (6.6)
Urinary/renal 55 (12.9) 38 (13.5) 35 (12.8) 65 (25.1)
Discontinued due to adverse events 39 (9.1) 41 (14.6) 65 (23.8) 73 (28.2)
Death 3 1 0 1
Adapted from Epilepsy Res. Porter et al; Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. © 2012, 
with permission from Elsevier.36
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in two studies33,35 but occurred in three (2%) patients in the 
placebo arm and nine (5.9%) patients in the 1200 mg/d group 
French et al’s study.34 Alterations in liver enzyme levels 
were noted rarely but were transient and did not require 
discontinuation from the studies.33–35 No changes in electro-
cardiography have been reported. Adverse events related to 
cardiac abnormalities were similar in the placebo (4%) and 
EZG (5%) groups.
While most of the reported side effects of EZG are 
similar to many other antiseizure medications in that they 
most commonly affect the CNS, EZG has one relatively 
unique and specific adverse effect, which is related to uri-
nary function.37 EZG had initially been noted to relax rat 
bladders39 as well as decrease bladder tension and contraction 
amplitude.40 As a result of this basic science data, urinary 
adverse events were recorded during the placebo-controlled 
trials. In Brodie et al’s trial,35 three patients were discharged 
from these trials for urinary symptoms, although the groups 
to which these patients were assigned were not delineated: 
one for nephritis and two for urinary hesitation. French et al34 
reported nine (5.9%) patients in the 1200 mg/d arm and one 
(0.7%) in the placebo arm with urinary hesitation and eight 
(5.2%) patients in the 1200 mg/d arm and two (1.3%) in the 
placebo arm with dysuria. In the pooled analysis, urinary or 
renal symptoms were reported in the EZG 1200 mg/d group 
(25%) almost twice as frequently as in the placebo (13%) 
group, although similar rates as in the placebo group were 
reported with 600 mg/d (14%) and 900 mg/d (13%).35,36 Other 
urinary symptoms and signs reported included urinary tract 
infections, polyuria, hematuria, proteinuria, and chromaturia. 
These adverse events were noted to diminish with time on the 
medication and were noted to be mild to moderate. Very few 
cases led to discontinuation (1% for both EZG and placebo). 
Due to the urinary symptoms, the FDA has required post-
marketing analysis and recording of urinary symptoms.
Some data from the open-label extension trial have 
now been published in a recent review.37 There continues 
to be no evidence of direct renal adverse events, although 
one participant did have reversible renal failure related to 
obstructive uropathy.37 Of note, four participants have now 
been reported with nephrolithiasis in the 1200 mg/d group.37 
However, based on the overall incidence of nephrolithiasis in 
the USA and EZG’s mechanism of action, it is not felt that 
ezogabine is an independent risk factor for nephrolithiasis at 
this time. Urinary crystals with an appearance similar to bili-
rubin have been reported in some participants.37 This could 
result in an abnormal urinalysis result but does not appear 
to be related to a risk for nephrolithiasis. Overall, it would 
seem prudent to monitor any patients on EZG for urologic 
symptoms and be cautious with those with risk factors for 
urinary obstruction.
No data are available on the safety of EZG use during 
pregnancy. As such, EZG is a pregnancy class C drug. In 
addition, there is a lack of established safety data on infants 
of breastfeeding mothers on EZG.
Other clinical applications
A variety of additional clinical applications beyond epi-
lepsy have been proposed for EZG. These include in 
neuromyotonia,41 neuropathic pain,42,43 mania, and addiction 
to psychostimulants.44 Other rodent models have demon-
strated a possible anti-dystonic effect.45 An in vitro study has 
demonstrated a possible anxiolytic effect of EZG.46 However, 
these other applications are still under investigation.
Discussion and conclusion
Epilepsy, despite several new medications that have been 
developed in the last few decades, continues to be refractory 
to medications in one-third of patients and can be a significant 
cause of morbidity and mortality. EZG is a new antiseizure 
drug with a novel mechanism of action. It is a potassium-
channel activator primarily active in the CNS, with alternate 
sites of action in the urinary bladder, gastrointestinal smooth 
muscle, and vascular smooth muscle.47,48
EZG has proven efficacy and is approved both in the USA 
and Europe for treatment of adults with intractable partial-
onset epilepsy. Given its novel mechanism of action, there 
is hope that EZG may be more effective for some patients 
with intractable epilepsy than other available antiseizure 
medications, although, overall, the efficacy data are fairly 
comparable to studies of other drugs in intractable patients. 
Early data demonstrate minimal interaction with medications 
other than lamotrigine and those interactions were deemed 
to be clinically insignificant.30
EZG is generally well tolerated and is rarely discontinued 
due to adverse events. The number of reported adverse events 
is also likely to be influenced by the forced fast titration 
schedule deemed necessary by the authors of the placebo-
controlled trials. Most of these adverse events were CNS 
related, such as somnolence and fatigue.
However, EZG has a novel adverse effect on the urinary 
tract – specifically, on the urinary bladder – both in animal 
models and in human trials. Urinary or secondary renal 
adverse effects are collectively relatively common, occurring 
in about 25% of patients in the highest-dose EZG group.36,37 
Symptoms from urinary adverse events were usually noted 
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to be minor or moderate, sometimes only involving labora-
tory abnormalities on urinalysis and rarely leading to dis-
continuation from the trial. However, urinary hesitancy and 
retention can be clinically significant problems. Thus, due to 
this novel side effect and the lack of a significant quantity of 
long-term data as to the severity and prevalence of urinary 
adverse events, the FDA has recommended a risk evaluation 
and mitigation strategy to further track the use of EZG in 
this regard. Overall, no long-term data currently exist as to 
the safety of EZG.
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